Pancreatic cancer harbors a poor prognosis due to the lack of effective systemic therapies. Here we interrogated means to target key effector pathways down-stream from KRAS. We found that combination treatment with MEK and CDK4/6 inhibitors was effective across a broad range of PDX models in delaying tumor progression. These effects were associated with stable cell cycle arrest, as well as the induction of multiple genes associated with interferon response and antigen presentation in an RB-dependent fashion. Using single cell sequencing and complementary approaches, we found that the combination of CDK4/6 and MEK inhibition had a significant impact on increasing T-cell infiltration and altering myeloid populations, while potently cooperating with immune checkpoint inhibitors. Together, these data indicate that there are canonical and non-canonical features of CDK4/6 and MEK inhibition that impact on the tumor and host that can contribute to durable control for tumors in combination with immune checkpoint inhibitor therapy.
Laboratory Animals. Mice were implanted subcutaneously with early passage PDX tumor fragments that have never been placed into culture. When tumors reached a volume of ~200 mm 3 they were randomized to treatment cohorts such that the starting volume across the cohorts was similar. Mice were treated for 3 weeks by gastric gavage with single agent or a combination. Palbociclib (PD-0332991, 100 mg/kg) diluted in 50 mM lactate buffer at pH 4.0, Trametinib (0.5 mg/kg) diluted in 0.5% hydroxypropyl cellulose and 0.2% Tween 80. Mice were treated daily for 5 days, followed by a 2-day break during 1 st week, and then every other day during 2 nd and 3 rd weeks for a total treatment time of 3 weeks. Tumor size was assessed every 2 days using digital calipers. Mice were sacrificed at either 6 days of treatment, 21 days of treatment, or 2 weeks after the end of treatment. Tumor measures were carried out independently by multiple laboratory members.
Syngeneic tumor model: C57BL/6J mice were subcutaneously injected with 4662 cells (3 x 10 6 ). When tumor volumes reached 150mm 3 mice were randomized to control, Trametinib, Palbociclib, and combination. Other groups were anti-PDL1, Palb +Tram + IgG, and Palb + Tram + anti-PDL1. Tumors were measured every other day with caliper and volume was calculated with the following equation: V = 0.5 ([greatest diameter] x [shortest diameter] 2 ).
Control group was given vehicle, Palbociclib was prepared in 50mM Na-Lactate Buffer (pH=4), Trametinib was prepared in 0.5% hydroxypropyl Cellulose and 0.2% Tween 80 in water, and dilution buffer was used for anti-PDL1 as well as IgG. Palbociclib and Trametinib were administered by gastric gavage. Anti-PDL1 and IgG were administered by intraperitoneal injection. Body weight was measured every other day. All the treatments lasted for 21 days or until tumor volumes reached 2000mm3. In mice where the tumor completely regressed, treatment was ceased, and the mice were monitored up to 30 days for tumor outgrowth. At the end of 30 th day, mice were re-challenged with 3x10^5 4662 cells and the tumor growth were monitored up to 45 days. Orthotopic models were performed as previously published 31 , mice were randomized at ~100 mm 3 as determined by MRI imaging 32 .
Single cell sequencing and analysis: C57BL6/J mice harboring 4662 tumors were sacrificed on treatment and dissociated by mincing and digestions with liberase (Sigma # 541020001) (2x15'). Resultant cells were stained with anti-mouse CD45 BUV395-conjugated antibody (BD Biosciences # 564616) and viability dye eFluor780 (Thermo Fisher #65-0865-14) and subjected to sorting. Single cell libraries are generated using the 10X Genomics platform. Cell suspensions are first assessed with Trypan Blue using a Countess FL automated cell counter (ThermoFisher), to determine concentration, viability and the absence of clumps and debris that could interfere with single cell capture. Cells are loaded into the Chromium Controller (10X Genomics) where they are partitioned into nanoliter-scale Gel Beads-in-emulsion with a single barcode per cell. Reverse transcription is performed and the resulting cDNA is amplified. The full-length amplified cDNA is used to generate gene expression libraries by enzymatic fragmentation, end-repair, a-tailing, adapter ligation, and PCR to add Illumina compatible sequencing adapters. The resulting libraries are evaluated on D1000 screentape using a TapeStation 4200 (Agilent Technologies), and quantitated using Kapa Biosystems qPCR quantitation kit for Illumina. They are then pooled, denatured, and diluted to 300pM with 1% PhiX control library added. The resulting pool is then loaded into the appropriate NovaSeq Reagent cartridge and sequenced on a NovaSeq6000 following the manufacturer's recommended protocol (Illumina Inc.) .
The raw sequencing data were processed using Cell Ranger software with mouse mm10 reference genome 33 . The filtered gene-barcode matrices which contain barcodes with the Unique Molecular Identifier (UMI) counts that passed the cell detection algorithm were used for Seurat single cell data analysis R package 34 . Cells with low RNA features (< 200) or high RNA feature (>5000) or high mitochondrial RNA contents (10%) were filtered out from the analysis.
Data from all samples are merged together and normalized using the SCTransform. Dimension reductions (PCA and UMAP) using the highly variable genes were calculated for clustering analysis using the first 30 principal components. SingleR package was utilized to identify the cell types and RNA velocity analysis were carried out using velocyto R package 35, 36 .
RESULTS:
In spite of genetic features that would be expected to yield sensitivity to CDK4/6 inhibitors pancreatic cancer cell lines are surprisingly resistant to this treatment 16, 37 . To systematically define cooperating agents, we carried out live cell imaging-based drug screens where the suppression of proliferation is directly monitored by evaluating cell number (Fig 1A   and S1 ). In this screen, MEK inhibitors were highly enriched for cooperating with the CDK4/6 inhibitor palbociclib. Validation studies with the MEK inhibitor trametinib demonstrated that these effects are due to cooperation relative to cell cycle inhibition as determined by BrdU incorporation ( Fig 1B) . Furthermore, dose response analysis showed that the drug interaction is synergistic as determined by Bliss analysis in multiple patient-derived cell models ( Fig 1C and   S1 ). To interrogate the mechanisms related to response, initially we evaluated how CDK4/6 inhibition may impact on features of signaling downstream from KRAS ( Fig S1) . These data showed that CDK4/6 inhibition had no effect related to canonical signaling through ERK, AKT, or MTOR pathways as determined by phosphorylation of ERK, AKT and S6 respectively ( Fig   S1) . However, the treatment with trametinib resulted in expected suppression of ERK activity and in several models also suppressed activity through the MTOR and AKT pathways ( Fig S1) , as has been recently reported in other RAS-driven tumors 17 . To determine the features of therapeutic cooperation, we interrogated canonical determinants of cell cycle control.
Treatment with CDK4/6 inhibitors lead to the adaptive upregulation of cyclin D1 and cyclin E in the pancreatic cancer cell lines ( Fig 1D) , consistent with prior findings 37, 38 . These adaptive features of CDK4/6 inhibition were ameliorated with the combined treatment with trametinib that yielded potent blockade of RB phosphorylation and suppression of cyclin A expression ( Fig 1D) .
Flow cytometry analysis using a FUCCI reporter for APC/CDH1 and SCF/SKP2 activity was used to determine the action of drug treatment on cell cycle regulatory activities. These data showed that the combination of CDK4/6 and MEK inhibition yielded a potent suppression of SCF/SKP2, yet APC/CDH1 remained active (Fig 1E and S2) . In parallel with these findings, we found that MEK inhibition induced p27Kip1 ( Fig S2) , which is an important determinant of response to CDK4/6 inhibition 10 . While CDK4/6 inhibition had a modest effect on CDK2 activity, MEK inhibition cooperated with CDK4/6 inhibition to decrease CDK2 kinase activity ( Fig   1F and Fig S2) . Consistent with the effects on CDK2 and RB activity, gene expression analysis illustrated pronounced suppression of E2F-target genes in multiple cell models with the combination treatment ( Fig 1G) . Thus, these data support the impact of coordinately targeting both a KRAS effector pathway (MEK1/2) and cell cycle (CDK4/6) to elicit pronounced cell cycle exit.
We utilized a panel of pancreatic cancer PDX models to delineate in vivo response to CDK4/6 and MEK inhibition. In multiple models, treatment with single agent MEK, or CDK4/6 inhibition had a transient impact on tumor growth (Fig 2A and 2B) . However, the combination significantly reduced tumor growth. Across a large number of individual PDX models (n=10 different PDXs and 368 individual tumors), we found that the combination significantly increased progression-free survival relative to CDK4/6 inhibition alone ( Fig 2C) . However, with the cessation of therapy at 21 days tumors progressed indicating the reversible cytostatic nature of the treatment. These responses were associated with enhanced suppression of Ki67 proliferation marker by immunohistochemistry, and the repression of E2F-target genes by RNA sequencing (Fig 2D and E) . Notably, in the PDX models (as in the cell models) the combination treatment limited phosphorylation of RB, and the expression of cyclin D1 and E ( Fig   S3) . Together, this work shows that the combination with CDK4/6 and MEK inhibition provides a putative therapeutic opportunity for the treatment of PDAC that is associated with profound cell cycle exit.
In order to understand means to expand on the cytostatic efficacy of the CDK4/6 and MEK inhibitor combination, we evaluated RNA sequencing data from treated PDAC models. In cell culture models we found that the combination of CDK4/6 and MEK inhibition elicited both the consistent suppression of genes, but also induced an equivalent number of genes ( Fig 3A) .
While the suppressed genes were strongly associated with cell cycle, the upregulated genes were associated with antigen presentation and features of interferon signaling ( Fig 3A, 3B and   S4 ). This signature of immune response is similar to that observed either with single agent MEK or CDK4/6 inhibition in other models 26, 39, 40 .
In particular, we observed that the combination induced the expression of multiple MHC genes (e.g. HLA-A, HLA-C) and genes involved in interferon signaling (e.g. STAT2 and IRF9) ( Fig 3C and S3 ). The induction of immune-related proteins was dependent on the presence of RB, as the 7310 cell line which is RB-deficient 41 failed to elicit this response ( Fig 3D and S4) . Further, evaluating independent treatments illustrated that MEK inhibition suppresses canonical target genes (e.g. DUSP5 and ETV1), as well as cell cycle (e.g. CCNA2 and PLK1), while eliciting the induction of the genes associated with interferon response and antigen presentation ( Fig 3E) . In this context, the suppression of MEK genes is RB-independent, while cell cycle and induced genes require RB as noted by the cell line 7310 ( Fig 3E) . The observed changes in gene expression were observed to induce secretion of CCL5 and CXCL10 that are downstream from interferon responses and associated with enhanced T-cell infiltration ( Fig S5) . The gene expression findings were also recapitulated in PDX models ( Fig 3F and S5) , where tumor selective transcripts were evaluated through the use of a hybrid mouse/human genome 42 . The interferon-like response has been suggested to represent a senescence-associated secretory phenotype (SASP). However, the lack no induction of IL6, IL8, and IL1ß in our data and little positive enrichment for the classical SASP signature ( Fig S6) . In addition to MEK inhibition, MTOR inhibitors can cooperate with CDK4/6 inhibitors in driving cell cycle exit 37 . The TORC1/2 inhibitor TAK228 results in potent cooperation with CDK4/6 inhibition in the suppression of cell cycle-regulated genes in PDX models and cell lines ( Fig S7) . However, the combination of palbociclib and TAK228 did not recapitulate the induction of the antigen-presentation genes ( Fig   S7) . These data validate that the combination of CDK4/6 and MEK inhibition is distinct in mediating both profound cell cycle exit and immunological response features in pancreatic cancer models. It has been reported in several tumor types that there is an inverse relationship between cell cycle and interferon-related gene expression signatures 43 . Using TCGA data we found that those tumors with high-index for proliferation, but low for immune response are associated with poor prognosis (Fig 3G, 3H and S8 ). Thus, in principle, shifting the transcriptional program toward that induced by MEK and CDK4/6 inhibition would be associated with improved survival coupling dual biological effects.
To functionally assess how the combination of CDK4/6 and MEK inhibition impacts on the immune system, we employed a syngeneic pancreatic cancer model derived from the KPC mouse model (the 4662 model) 29 . This model is highly aggressive and neither CDK4/6 inhibition nor MEK inhibition alone had a significant impact on either cell growth or tumor growth in C57BL6/J mice ( Fig 4A and 4B) . However, consistent with the findings in the patient-derived models the combination treatment with MEK and CDK4/6 inhibition delayed the progression of this model, albeit even within 14 days there was tumor growth on treatment ( Fig 4B) . To define how CDK4/6 and MEK inhibition impacts on the immunological tumor microenvironment and immune-checkpoint inhibitor therapy single cell sequencing was performed. Mice bearing established 4662 tumors were treated with palbociclib and trametinib, or a triple combination with anti-PD-L1. Tumors were dissociated and the CD45+ fraction was isolated by fluorescentactivated cell sorting ( Fig 4C) . Single cell RNA sequencing was performed using the 10x chromium method. Consistent with the enrichment approach, all cells were positive for the CD45 gene (PTPRC) irrespective of treatment ( Fig 4C) . Dimensional clustering algorithms defined 12 populations of cells that capture lymphoid, myeloid, monocytic, and B-cell components of the tumor (Fig 4D and S9) . The myeloid compartment was defined by classical phenotyping markers (CD33, S100A8, and ITGAM), with two dominant myeloid-macrophage populations (clusters 0 and 2) ( Fig 4E) . Treatment with palbociclib and trametinib lead to a complete switch in the dominant macrophage population present in the control tumors (Fig 4F and G) . Specifically, the myeloid-macrophages were suppressed for immediate early genes (e.g. EGR1, JUNB, ETS2, FOS) that are downstream from MEK/ERK signaling 44 . These changes were accompanied by down-regulation of PTGS2, VEGFA, and MMP9 that are associated with immune-suppressive M2-like macrophages ( Fig 4H and S10) 45 . Concordantly, with treatment there was induction of genes associated with iron-metabolism (FTL1, FLH1, and HMOX1) and macrophage functions (BNIP3L, CTSD) that are typically associated with immuneactivating M1-like macrophages ( Fig 4H) 45 . Additionally, top induced genes include CCL3, CCL4, and CCL6 that are involved in T-cell, dendritic cell, B-cell, and NK cell infiltration ( Fig   4H) . This shift in macrophage populations was also observed in tumors treated with the triplet that includes anti-PD-L1 ( Fig 4G and H) . Under these treatments there was only a modest alteration in the neutrophil population (cluster 3).
The lymphoid compartment of the tumor encompassed multiple sub-types of T-cells and NK cells as indicated by conventional markers (Fig 5A, 5B, S11 ). With treatment the lymphoid populations were clearly enhanced with both CDK4/6 and MEK inhibition as well as the triplet combining these inhibitors with anti-PD-L1 ( Fig 5C) . The most common CD8+ T-cell population (cluster 1) almost doubled with treatment of palbociclib and trametinib and was further enhanced with anti-PD-L1. This T-cell population is GZMB and PRF1 positive, characteristics of cytotoxic function. Interestingly, other populations were more modestly induced or did not change with the doublet (Fig 5D) . This includes NK-cells and a proliferative T-cell population (cluster 9) which was surprisingly unaffected by CDK4/6 and MEK inhibition ( Fig 5D and S12) .
The inclusion of anti-PD-L1 treatment further enhanced the T-cell infiltrate with significant increases in veritably all populations, most notably the NK cell population ( Fig 5D) . In the control tumors, there was a significant skewing toward myeloid infiltration, while treatment with CDK4/6 and MEK inhibitors increases the lymphoid infiltrate which, was further enhanced with anti-PDL1 ( Fig 5E) . These findings were confirmed in independent tissues using anti-CD8 and CD163 immunostaining and multi-spectral imaging (Fig 5F and S12) . The monocytic populations were more limited in the treatment-naïve tumors, but augmented with treatment, as were relatively rare BATF3+ dendritic cell populations ( Fig S13) , Velocity analysis suggests that the monocytic pools were transiting toward the dendritic cell populations ( Fig S13) . In addition, while limited, the number of B-cells within the tumor increased. Together, these data suggest an overall increase in tumor immunogenicity with CDK4/6 and MEK inhibition. The 4662 syngeneic model is largely resistant to anti-PD-L1 treatment consistent with other studies 29 ;
however, the combination of CDK4/6 and MEK inhibition with anti-PD-L1 was highly effective yielding regression of the tumor (Fig 5G) . This treatment was well-tolerated as indicated by lack of weight loss ( Fig S14) , and the combination of both CDK4/6 and MEK inhibitor was required for the potent cooperation with anti-PD-L1 ( Fig S14) .
In a small cohort of animals followed long-term, tumor cure and resistance to subsequent challenge was also observed ( Fig   S14) .
To confirm the activity, we employed orthotopic models, where tumor cells were introduced into the pancreas and tumor engraftment and volume was assessed by magnetic resonance imaging (MRI) (Fig. 5H ). Mice were randomized to treatment groups, and as in the subcutaneous models, there was more profound disease control with the triplet combining CDK4/6 and MEK inhibitors and anti-PD-L1. To specifically interrogate the significance of the CD8+ T-cells for this therapeutic response, mice were coordinately treated with anti-CD8, which depleted CD8+ cells in the tumor bed ( Fig S14) , and reversed the impact of anti-PD-L1 ( Fig 5H) .
Together, these studies underscore the potency of combining targeted and immunotherapy for the treatment of PDAC and illuminate previously unrecognized contributions of targeted therapies on the tumor-immune microenvironment.
DISCUSSION:
As a therapy recalcitrant disease, combinatorial means to target pancreatic cancer will assuredly be required. While CDK4/6 inhibitors have been found to be effective in ER+ breast cancer and FDA-approved for that indication, clinical advances in additional
indications have yet to mature 46 . As a tumor driven by KRAS and CDKN2A loss, it would be expected that CDK4/6-inhibition would have dominant effects in pancreatic cancer. The data herein reinforce the finding that cell cycle plasticity enables escape from CDK4/6 inhibitors;
however, by unbiased drug screens MEK inhibitors emerged as key cooperative agents to block that plasticity and couple CDK4/6 inhibition to the activation of RB, suppression of CDK2, and repression of E2F target genes. These interactions are synergistic in cell culture and highly potent in all PDX models representing 10 different patients. While the combination is highly effective, with cessation of treatment cells will re-enter the cell cycle (not shown) and tumors ultimately progress. Additionally, in very fast growing tumors e.g. 4662 model, progression occurs on therapy and reinforces the need for an adjuvant strategies to complement the cell cycle inhibition.
In evaluating the effect of CDK4/6 and MEK inhibition on gene expression, we observed a large number of genes that are repressed or activated and could yield a specific vulnerability beyond the cell cycle. For example, there is potent suppression of EZH2 and additional chromatin modifiers as well as inhibition of DNA repair mechanisms that could confer sensitivity to sensitivity to diverse therapeutics. A noted feature of the response to CDK4/6 and MEK inhibition is the upregulation of interferon and antigen presentation that has been observed in other tumor types 27, 47 . This signature is related to cell cycle arrest and is RB-dependent;
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